Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2026Cancer CytopathologyOpen Access

Refining risk stratification after indeterminate urinary cytology: Evidence from Bladder EpiCheck

View Full Paper
Ask AI
Bookmark
Share

Authors

CMClàudia MercaderMIMercedes Ingelmo‐TorresFRFiorella L. Roldan

Discussion

Loading...

Member takes

Overview

Prospective study reveals Bladder EpiCheck combined with repeat cytology improves urothelial carcinoma detection after indeterminate tests, suggesting enhanced surveillance stratification.

Key Points

  • To assess the diagnostic accuracy of the Bladder EpiCheck test for identifying urothelial carcinoma and high-grade events in patients with indeterminate cytology and negative cystoscopy.
  • Prospective study of 63 patients presenting with indeterminate urinary cytology and negative cystoscopy between October 2022 and April 2024.
  • Repeated urine samples were evaluated concurrently with urinary cytology and the Bladder EpiCheck test, with patients followed for 1 year.
  • Logistic regression models were constructed to predict urothelial carcinoma and high-grade recurrence risks based on combined test results.
  • Urothelial carcinoma occurred in 32 patients (51%), of which 25 (78%) were high-grade events.
  • Bladder EpiCheck demonstrated significantly higher sensitivity than repeat cytology for detecting urothelial carcinoma (80% vs. 17%; p < .001) and high-grade disease (80% vs. 25%; p < .001), whereas repeat cytology showed higher specificity (96% vs. 59%; p = .02).
  • Prognostic models combining repeat cytology with Bladder EpiCheck outperformed single-test models in predicting urothelial carcinoma and high-grade events.

Cite This Study

Mercader et al. (2026) studied this question.

synapsesocial.com/papers/6aa27a8e58559d80afc7328bhttps://doi.org/10.1002/cncy.70141
View Full Paper
Ask AI
Bookmark
Share